Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MELINTA THERAPEUTICS, INC. /NEW/MLNT · Entity 154249 | Director | June 11, 2019 | June 12, 2019 |
| MOMENTA PHARMACEUTICALS INCMNTA · Entity 146313 | Director | June 19, 2019 | June 21, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MELINTA THERAPEUTICS, INC. /NEW/
Report date June 11, 2019 · Filed June 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Melinta Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 30,000 |
Reported balance
After 2019-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date.
MOMENTA PHARMACEUTICALS INC
Report date June 19, 2019 · Filed June 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,590 |
Reported balance
After 2019-06-20 transaction · row 1
1 source rowRow 1 · 2019-06-20 · Exercise / conversion · Acquired 4,356 · Balance 15,590 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2029-06-19 | Direct | 25,000 |
Reported balance
After 2019-06-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-19 · Grant · Acquired 25,000 · Balance 25,000 F1: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Koestler's continued service to the Company. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-06-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-06-20 · Exercise / conversion · Disposed 4,356 · Balance 0 F2: Restricted Stock Units convert into common stock on a one-for-one basis. F3: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Koestler's continued service to the Company.
F2: Restricted Stock Units convert into common stock on a one-for-one basis.
F3: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Merck & Co., Inc.
Report date November 03, 2009 · Filed November 04, 2009
Section 16 reporting ended · disclosed 2009-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 1
1 source rowRow 1 · 2009-11-03 · Disposition to issuer · Disposed 59,666 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. |
| Deferred Stock Unit AwardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2009-11-03 · Disposition to issuer · Disposed 75,000 · Balance 0 F2: Each deferred stock unit ("DSU") is the economic equivalent of one share of common stock. F4: In connection with the Merger, the cash value of the DSU's will be paid to the reporting person in accordance with the terms of the Issuer's 2006 Stock Incentive Plan. F3: The DSU's became vested upon the closing of the Merger. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.23 · Expires 2013-05-18 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2009-11-03 · Disposition to issuer · Disposed 90,000 · Balance 0 F6: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.12 · Expires 2013-08-17 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2009-11-03 · Disposition to issuer · Disposed 150,000 · Balance 0 F6: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.57 · Expires 2014-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2009-11-03 · Disposition to issuer · Disposed 240,000 · Balance 0 F6: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.70 · Expires 2015-04-24 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2009-11-03 · Disposition to issuer · Disposed 100,000 · Balance 0 F6: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2015-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2009-11-03 · Disposition to issuer · Disposed 220,000 · Balance 0 F6: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.91 · Expires 2016-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2009-11-03 · Disposition to issuer · Disposed 209,700 · Balance 0 F6: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.20 · Expires 2014-02-22 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2009-11-03 · Disposition to issuer · Disposed 70,000 · Balance 0 F6: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.
F2: Each deferred stock unit ("DSU") is the economic equivalent of one share of common stock.
F3: The DSU's became vested upon the closing of the Merger.
F4: In connection with the Merger, the cash value of the DSU's will be paid to the reporting person in accordance with the terms of the Issuer's 2006 Stock Incentive Plan.
F5: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
F6: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2019 Filed Jun 21, 2019 16:14 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Unit · Derivative | 4,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008021 · edgar.xml · derivative · entry 3 Koestler Thomas P · CIK 0001373605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,356 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. F3 · derivative.expiration_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 16:14 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 4,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008021 · edgar.xml · nonDerivative · entry 1 Koestler Thomas P · CIK 0001373605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:14 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001179110-19-008021 · edgar.xml · derivative · entry 2 Koestler Thomas P · CIK 0001373605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Koestler's continued service to the Company. Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 13:36 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | GrantMelinta Restricted Stock Units · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001461993-19-000029 · wf-form4_156036097261620.xml · derivative · entry 1 Koestler Thomas P · CIK 0001373605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Melinta Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date. F1 · derivative.expiration_date: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date. Read SEC document |
| June 20, 2018 Filed Jun 25, 2018 16:29 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008992 · edgar.xml · derivative · entry 4 Koestler Thomas P · CIK 0001373605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. F5 · derivative.expiration_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. Read SEC document |
| June 20, 2018 Filed Jun 25, 2018 16:29 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 4,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008992 · edgar.xml · derivative · entry 3 Koestler Thomas P · CIK 0001373605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,356 Underlying: Common Stock · 4,356 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock. F3 · derivative.exercise_date: Represents 4,356 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Koestler's continued service to the Company. F3 · derivative.expiration_date: Represents 4,356 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Koestler's continued service to the Company. Read SEC document |
| June 20, 2018 Filed Jun 25, 2018 16:29 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 8,855 | $0.00 Strike: $22.30 | $0.00 |
DisclosureSEC source: 0001179110-18-008992 · edgar.xml · derivative · entry 2 Koestler Thomas P · CIK 0001373605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,855 Underlying: Common Stock · 8,855 shares Expires 2028-06-20 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Koestler's continued service to the Company. Read SEC document |
| June 20, 2018 Filed Jun 25, 2018 16:29 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008992 · edgar.xml · nonDerivative · entry 1 Koestler Thomas P · CIK 0001373605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 16:59 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | GrantStock Option (right to buy) · Derivative | 9,100 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0000899243-18-016641 · doc4.xml · derivative · entry 2 Koestler Thomas P · CIK 0001373605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Underlying: Common Stock · 9,100 shares Expires 2028-04-20 F1 · date: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 16:59 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0000899243-18-016641 · doc4.xml · derivative · entry 1 Koestler Thomas P · CIK 0001373605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-04-20 F1 · date: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018. F2 · derivative.exercise_date: One-third of the shares underlying the stock option will vest and become exercisable on April 20, 2019. The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on April 20, 2019. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 16:01 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-009446 · edgar.xml · derivative · entry 2 Koestler Thomas P · CIK 0001373605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,734 Underlying: Common Stock · 5,734 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock. F3 · derivative.exercise_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Koestler's continued service to the Company. F3 · derivative.expiration_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Koestler's continued service to the Company. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 16:01 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 11,207 | $0.00 Strike: $17.20 | $0.00 |
DisclosureSEC source: 0001179110-17-009446 · edgar.xml · derivative · entry 1 Koestler Thomas P · CIK 0001373605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,207 Underlying: Common Stock · 11,207 shares Expires 2027-06-20 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Koestler's continued service to the Company. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (right to buy) · Derivative | 209,700 | Not disclosed Strike: $22.91 | Not disclosed |
DisclosureSEC source: 0001209191-09-051070 · c91879_4x1.xml · derivative · entry 9 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 209,700 shares Expires 2016-04-30 F6 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (right to buy) · Derivative | 220,000 | Not disclosed Strike: $18.85 | Not disclosed |
DisclosureSEC source: 0001209191-09-051070 · c91879_4x1.xml · derivative · entry 8 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 220,000 shares Expires 2015-04-30 F6 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (right to buy) · Derivative | 100,000 | Not disclosed Strike: $20.70 | Not disclosed |
DisclosureSEC source: 0001209191-09-051070 · c91879_4x1.xml · derivative · entry 7 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 100,000 shares Expires 2015-04-24 F6 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (right to buy) · Derivative | 240,000 | Not disclosed Strike: $31.57 | Not disclosed |
DisclosureSEC source: 0001209191-09-051070 · c91879_4x1.xml · derivative · entry 6 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 240,000 shares Expires 2014-04-30 F6 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (Right to Buy) · Derivative | 70,000 | Not disclosed Strike: $18.20 | Not disclosed |
DisclosureSEC source: 0001209191-09-051070 · c91879_4x1.xml · derivative · entry 5 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 70,000 shares Expires 2014-02-22 F6 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (right to buy) · Derivative | 150,000 | Not disclosed Strike: $16.12 | Not disclosed |
DisclosureSEC source: 0001209191-09-051070 · c91879_4x1.xml · derivative · entry 4 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 150,000 shares Expires 2013-08-17 F6 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (right to buy) · Derivative | 90,000 | Not disclosed Strike: $19.23 | Not disclosed |
DisclosureSEC source: 0001209191-09-051070 · c91879_4x1.xml · derivative · entry 3 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 90,000 shares Expires 2013-05-18 F6 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerDeferred Stock Unit Award · Derivative | 75,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-09-051070 · c91879_4x1.xml · derivative · entry 2 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit ("DSU") is the economic equivalent of one share of common stock. F4 · price: In connection with the Merger, the cash value of the DSU's will be paid to the reporting person in accordance with the terms of the Issuer's 2006 Stock Incentive Plan. F3 · derivative.exercise_date: The DSU's became vested upon the closing of the Merger. F4 · derivative.expiration_date: In connection with the Merger, the cash value of the DSU's will be paid to the reporting person in accordance with the terms of the Issuer's 2006 Stock Incentive Plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerCommon Shares | 59,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051070 · c91879_4x1.xml · nonDerivative · entry 1 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Read SEC document |
| May 01, 2009 Filed May 5, 2009 18:06 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantOption (right to buy) · Derivative | 209,700 | Not disclosed Strike: $22.91 | Not disclosed |
DisclosureSEC source: 0000310158-09-000051 · koe729.xml · derivative · entry 1 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,700 Underlying: Common Shares · 209,700 shares Expires 2016-04-30 F2 · price: Not Applicable. F1 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2006 Stock Incentive Plan and exercisable in one-third increments on May 1 of 2010, 2011 and 2012. The vesting of 41,940 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the 2009 year. Read SEC document |
| April 01, 2009 Filed Apr 3, 2009 19:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionDeferred Stock Unit Award · Derivative | 14,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-09-000035 · koe720.xml · derivative · entry 3 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 14,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 01, 2009 Filed Apr 3, 2009 19:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | Tax withholdingCommon Shares | 5,744 | $23.70 | $136,132.80 |
DisclosureSEC source: 0000310158-09-000035 · koe720.xml · nonDerivative · entry 2 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,666 Read SEC document |
| April 01, 2009 Filed Apr 3, 2009 19:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionCommon Shares | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-09-000035 · koe720.xml · nonDerivative · entry 1 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document |
| May 01, 2008 Filed May 5, 2008 20:54 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantOption (right to buy) · Derivative | 220,000 | Not disclosed Strike: $18.85 | Not disclosed |
DisclosureSEC source: 0000310158-08-000036 · koe664.xml · derivative · entry 1 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Shares · 220,000 shares Expires 2015-04-30 F2 · price: Not Applicable. F1 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2006 Stock Incentive Plan and exercisable in one-third increments on May 1 of 2009, 2010 and 2011. The vesting of 44,000 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the 2008 year. Read SEC document |
| April 25, 2008 Filed Apr 29, 2008 19:55 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionDeferred Stock Unit Award · Derivative | 15,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-08-000018 · koe653.xml · derivative · entry 3 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,000 Underlying: Common Shares · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 25, 2008 Filed Apr 29, 2008 19:55 UTC | Merck & Co., Inc. SGP · Entity 2807 | Tax withholdingCommon Shares | 6,186 | $18.64 | $115,307.04 |
DisclosureSEC source: 0000310158-08-000018 · koe653.xml · nonDerivative · entry 2 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,410 Read SEC document |
| April 25, 2008 Filed Apr 29, 2008 19:55 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionCommon Shares | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-08-000018 · koe653.xml · nonDerivative · entry 1 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document |
| August 18, 2007 Filed Aug 21, 2007 19:13 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionDeferred Stock Unit Award · Derivative | 30,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-07-000068 · koe631.xml · derivative · entry 3 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,000 Underlying: Common Shares · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document |
| August 18, 2007 Filed Aug 21, 2007 19:13 UTC | Merck & Co., Inc. SGP · Entity 2807 | Tax withholdingCommon Shares | 13,905 | $29.56 | $411,031.80 |
DisclosureSEC source: 0000310158-07-000068 · koe631.xml · nonDerivative · entry 2 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,596 Read SEC document |
| August 18, 2007 Filed Aug 21, 2007 19:13 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionCommon Shares | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-07-000068 · koe631.xml · nonDerivative · entry 1 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document |
| May 01, 2007 Filed May 3, 2007 20:44 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantOption (right to buy) · Derivative | 240,000 | Not disclosed Strike: $31.57 | Not disclosed |
DisclosureSEC source: 0000310158-07-000036 · koe609.xml · derivative · entry 1 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Shares · 240,000 shares Expires 2014-04-30 F2 · price: Not Applicable. F1 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2006 Stock Incentive Plan and exercisable in one-third increments on May 1 of 2008, 2009 and 2010. The vesting of 48,000 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the 2007 year. Read SEC document |
| December 01, 2006 Filed Dec 5, 2006 20:13 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionDeferred Stock Unit Award · Derivative | 12,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-06-000151 · koe582.xml · derivative · entry 3 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,000 Underlying: Common Shares · 12,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document |
| December 01, 2006 Filed Dec 5, 2006 20:13 UTC | Merck & Co., Inc. SGP · Entity 2807 | Tax withholdingCommon Shares | 5,562 | $21.93 | $121,974.66 |
DisclosureSEC source: 0000310158-06-000151 · koe582.xml · nonDerivative · entry 2 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,501 Read SEC document |
| December 01, 2006 Filed Dec 5, 2006 20:13 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionCommon Shares | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-06-000151 · koe582.xml · nonDerivative · entry 1 Koestler Thomas P · CIK 0001373605 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.